
Keywords: Antibody-drug conjugate; Guanylyl cyclase C; GI malignancies; ADCs; Antibody-drug conjugates; CDX-2; Caudal type homeobox transcription factor-2; DAR; Drug-to-antibody ratio; GC; Guanylyl cyclase; GCC; Guanylyl cyclase C; GEJ; Gastroesophageal junctio